Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results. 

Jury still out on IL-6 drugs in COVID-19 following prelimina...

There is a growing body of evidence that already-approved IL-6 could be used as treatments for COVID-19 following newly published clinical trial data – but the jury is out on whether they c

Regeneron’s Ebola drug heading for October verdict from FDA

Sanofi begins trial of Kevzara against COVID-19 complication...

Sanofi and Regeneron are throwing an already-approved drug at COVID-19, testing Kevzara (sarilumab) in patients hospitalised with severe disease.

NICE rejects NHS funding Sanofi/Regeneron's Dupixent in asth...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

GSK's Walmsley gets £2.5m pay rise after strong 2019

There can’t be many people in the UK who enjoyed a £2.5 million pay rise this year – but that’s what GlaxoSmithKline boss Emma Walmsley got after a strong year for sales.